AR107711A2 - COMPRESSED PHARMACEUTICAL, PHARMACEUTICAL GRANULES AND PROCEDURE FOR PREPARATION, ORAL SOLID PHARMACEUTICAL FORM, CAPSULE - Google Patents
COMPRESSED PHARMACEUTICAL, PHARMACEUTICAL GRANULES AND PROCEDURE FOR PREPARATION, ORAL SOLID PHARMACEUTICAL FORM, CAPSULEInfo
- Publication number
- AR107711A2 AR107711A2 ARP170100459A ARP170100459A AR107711A2 AR 107711 A2 AR107711 A2 AR 107711A2 AR P170100459 A ARP170100459 A AR P170100459A AR P170100459 A ARP170100459 A AR P170100459A AR 107711 A2 AR107711 A2 AR 107711A2
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical
- diluent
- tablet
- free
- capsule
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Comprimido farmacéutico que comprende la sal de bis-(monoetanolamina) del ácido 3’-[(2Z)-[1-(3,4-dimetilfenil)-1,5-dihidro-3-metil-5-oxo-4H-pirazol-4-ilideno]hidrazino]-2’-hidroxi-[1,1’-bifenil]-3-carboxílico (eltrombopag olamina), donde el comprimido fue realizado por el uso de un diluyente o diluyentes que están libres de metales de coordinación y/o que están libres de azúcares reductores. Dicho comprimido fabricado por medio de un proceso de granulación en húmedo y que tiene el 90% de las partículas de fármaco de un tamaño de partículas mayor de 10 micrómetros pero menor de 90 micrómetros. Cápsula farmacéutica, forma de dosificación y gránulos farmacéuticos correspondientes. Uso para preparar un medicamento útil para tratar la trombocitopenia o para agonizar el receptor de TPO en un ser humano que lo necesita. Proceso para preparar formas de dosificación correspondientes. Reivindicación 8: Un comprimido farmacéutico de acuerdo con ia reivindicación 1 caracterizada porque comprende: a) de 2% a 65% eltrombopag olamina; b) de 25% a 89% de diluyente; c) hasta 8% aglutinante; d) hasta 2% de lubricante; y e) de 4% a 12% de desintegrante. Reivindicación 17: Un comprimido farmacéutico de acuerdo con la reivindicación 8, caracterizado porque el componente diluyente comprende un azúcar no reductor y celulosa microcristalina. Reivindicación 18: Un comprimido farmacéutico de acuerdo con la reivindicación 17, caracterizado porque el azúcar no reductor es manitol, el aglutinante es polivinilpirrolidona, el desintegrante es glicolato de almidón sódico y el lubricante es estearato de magnesio. Reivindicación 25: Una forma farmacéutica oral sólida caracterizada porque Bis (monoetanolamina) del ácido 3’-[(2Z)-[1-(3,4-dimetilfenil)-1,5-dihidro-3-metil-5-oxo-4H-pirazoi-4-ilideno]hidrazino}-2’-hidroxi-[1,1’-bifenil}-3-carboxílico en la que la forma farmacéutica oral sólida se prepara usando un diluyente o diluyentes que están sustancialmente libres de metales de coordinación y/o que están sustancialmente libres de azúcares reductores.Pharmaceutical tablet comprising the bis- (monoethanolamine) salt of 3 '- [(2Z) - [1- (3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H-pyrazole acid -4-ylidene] hydrazino] -2'-hydroxy- [1,1'-biphenyl] -3-carboxylic acid (eltrombopag olamine), where the tablet was made by using a diluent or diluents that are free of coordination metals and / or that are free of reducing sugars. Said tablet manufactured by means of a wet granulation process and having 90% of the drug particles of a particle size greater than 10 micrometers but less than 90 micrometers. Pharmaceutical capsule, dosage form and corresponding pharmaceutical granules. Use to prepare a useful medication to treat thrombocytopenia or to agonize the TPO receptor in a human being in need. Process to prepare corresponding dosage forms. Claim 8: A pharmaceutical tablet according to claim 1 characterized in that it comprises: a) from 2% to 65% eltrombopag olamine; b) from 25% to 89% diluent; c) up to 8% binder; d) up to 2% lubricant; and e) from 4% to 12% disintegrant. Claim 17: A pharmaceutical tablet according to claim 8, characterized in that the diluent component comprises a non-reducing sugar and microcrystalline cellulose. Claim 18: A pharmaceutical tablet according to claim 17, characterized in that the non-reducing sugar is mannitol, the binder is polyvinyl pyrrolidone, the disintegrant is sodium starch glycolate and the lubricant is magnesium stearate. Claim 25: A solid oral pharmaceutical form characterized in that Bis (monoethanolamine) of 3 '- [(2Z) - [1- (3,4-dimethylphenyl) -1,5-dihydro-3-methyl-5-oxo-4H acid -pyrazoi-4-ylidene] hydrazino} -2'-hydroxy- [1,1'-biphenyl} -3-carboxylic acid in which the solid oral pharmaceutical form is prepared using a diluent or diluents that are substantially free of coordination metals and / or that are substantially free of reducing sugars.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91576107P | 2007-05-03 | 2007-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107711A2 true AR107711A2 (en) | 2018-05-23 |
Family
ID=38777752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100459A AR107711A2 (en) | 2007-05-03 | 2017-02-23 | COMPRESSED PHARMACEUTICAL, PHARMACEUTICAL GRANULES AND PROCEDURE FOR PREPARATION, ORAL SOLID PHARMACEUTICAL FORM, CAPSULE |
Country Status (3)
| Country | Link |
|---|---|
| AP (1) | AP2007004090A0 (en) |
| AR (1) | AR107711A2 (en) |
| UA (1) | UA96261C2 (en) |
-
2007
- 2007-07-27 AP AP2007004090A patent/AP2007004090A0/en unknown
- 2007-10-05 UA UAA200711046A patent/UA96261C2/en unknown
-
2017
- 2017-02-23 AR ARP170100459A patent/AR107711A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA96261C2 (en) | 2011-10-25 |
| AP2007004090A0 (en) | 2007-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059656A1 (en) | PHARMACEUTICAL COMPRESSED UNDERSTANDING BIS SALT - (MONOETHANOLAMINE) OF ACID 3 '- [(2Z) - [1- (3,4- DIMETHYLPHENYL) -1,5- DIHYDRO-3- METHYL-5 OXO- 4H-PIRAZOL- 4- ILIDENO} HYDRAZINE} -2 'HYDROXY- {1,1'- BIFENYL] -3- CARBOXILICO [ELTROMBOPAG OLAMINA), PHARMACEUTICAL CAPSULA, DOSAGE FORM AND GRANULO | |
| ECSP19046865A (en) | CONJUGATES INCLUDING A GLP-1 / GLUCAGON DUAL AGONIST, A CONNECTOR AND HYALURONIC ACID | |
| FI3716979T3 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| UY30819A1 (en) | DERIVATIVES OF PIRAZOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS | |
| DOP2011000343A (en) | PIRIDINE TIENO DERIVATIVES [2,3-B] AS VIRAL REPLICATION INHIBITORS | |
| MX2012007410A (en) | Novel antiviral compounds. | |
| EA201692214A1 (en) | NUCLEAR NUCLEAR RECEPTOR SUBSTANCES | |
| CO6300953A2 (en) | MINERALCORTICOID RECEIVER ANTAGONISTS AND METHODS OF USE | |
| MX2009004362A (en) | Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk. | |
| EA201490477A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPYLENE GLYCOL-HYDRATE DAPAGLYFLOSINE | |
| UY35624A (en) | USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE | |
| MX343358B (en) | Ulipristal acetate tablets. | |
| ATE412647T1 (en) | SUBSTITUTED N-ARYLPYRROLIDINE AS SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR | |
| RU2010101797A (en) | PHARMACEUTICAL SOLID PRODUCT CONTAINING BENZAZEPINE AND METHOD FOR PRODUCING IT | |
| WO2016060517A3 (en) | Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases | |
| CR20110704A (en) | COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION | |
| Chattopadhyay et al. | Ethnomedicines and ethnomedicinal phytophores against herpesviruses | |
| EA201590797A1 (en) | PREPARATIONS WITH THE MODIFIED PROBE RELEASE | |
| NO20083535L (en) | Alpha-crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it | |
| PH12016500042A1 (en) | Stabilized pharmaceutical dosage forms comprising atrasentan | |
| GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
| Wang et al. | Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: design, synthesis, and biological evaluation | |
| PE20190608A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING MINERALOCORTICOID RECEIVER ANTAGONIST AND ITS USE | |
| RU2015113031A (en) | The use of 3-n-butyl isoindoline ketones in the preparation of medicines for the prevention and treatment of cerebral infarction | |
| AR107711A2 (en) | COMPRESSED PHARMACEUTICAL, PHARMACEUTICAL GRANULES AND PROCEDURE FOR PREPARATION, ORAL SOLID PHARMACEUTICAL FORM, CAPSULE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |